文献速递临床试验与 GCP

法莫替丁改善住院COVID-19患者结局的随机对照试验方案结构化摘要

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-10-13

该文为一项III期随机对照试验方案的结构化摘要,旨在评估法莫替丁对COVID-19住院患者康复过程的影响。试验采用平行分组、安慰剂对照、单盲、隐藏分配设计,计划入组20例SARS-CoV-2 PCR阳性住院患者,干预组接受标准治疗联合口服法莫替丁160 mg每日四次至出院(最长14天),对照组接受标准治疗联合安慰剂。主要结局包括体温、呼吸频率、氧饱和度、肺部浸润、乳酸脱氢酶和全血细胞计数,于基线及干预后第14天或出院日测量。

要点

  • 法莫替丁160 mg每日四次联合标准治疗,最长14天,对照为安慰剂。
  • 计划入组20例PCR阳性住院患者,随机分为两组各10例。
  • 主要结局于基线及第14天或出院日评估体温、呼吸、氧饱和、肺部浸润、LDH和血常规。

核心结论

  • 该方案旨在评估法莫替丁对COVID-19住院患者康复过程的影响,尚未报告结果。

研究设计与样本

  • III期随机对照试验,平行分组、安慰剂对照、单盲、隐藏分配。
  • 计划入组20例PCR阳性住院患者,随机分为干预组和对照组各10例。
  • 因无前期研究,未进行样本量计算假设。

关键数值与推荐

  • 干预组:标准治疗联合口服法莫替丁160 mg每日四次,至出院日,最长14天。
  • 对照组:标准治疗联合安慰剂,相同用法。
  • 主要结局于基线及干预后第14天或出院日测量体温、呼吸频率、氧饱和度、肺部浸润、乳酸脱氢酶和全血细胞计数。
  • 排除标准包括免疫抑制、终末期肾病、中重度肾功能不全、肝病史、丙肝感染或酗酒、G6PD缺乏、ALT/AST高于正常上限5倍、长QT病史或证据、银屑病或卟啉症、妊娠、使用口服避孕药及特定药物、对研究药物过敏。

局限性

  • 样本量仅20例,因无前期研究未做样本量计算假设。
  • 单盲设计,主要研究者、护理者、数据收集者和结局评估者知晓分组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to investigate the effect of Famotidine on the recovery process of COVID-19 patients. TRIAL DESIGN: This phase III randomized clinical trial was designed with two parallel arms, placebo-controlled, single-blind, and concealed allocation. PARTICIPANTS: All COVID-19 patients admitted to Shahid Mohammadi Hospital in Bandar Abbas whose PCR test results are positive for SARS-Cov-2 and sign the written consent of the study are included in the study and immunocompromised patients, end-stage renal disease, moderate renal failure (clearance Creatinine 30 to 50 ml/min) or stage 4 severe chronic kidney disease or need for dialysis (creatinine clearance lesser than 30 ml/min), history of liver disease, hepatitis C infection or alcoholism, Glucose 6 phosphate dehydrogenase deficiency(G6PD), the ratio of Alanine transaminase to Aspartate transaminase 5 times above the normal limit, history or evidence of long QT segment on Electrocardiogram, psoriasis or porphyria, pregnancy, use of oral contraceptives, Dasatinib, Neratinib, Ozanimod, Pazopanib, Rilpivirine, Siponimod and/or Tizanidine and allergies to any study drug are excluded. INTERVENTION AND COMPARATOR: Intervention group receives standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 and oral famotidine 160 mg (Manufactured by Chemidarou Pharmaceutical Company) four times a day until the day of discharge, for a maximum of fourteen days. Comparator group receives standard drug therapy according to the treatment protocols of the National Committee of COVID-19 and placebo in the same dosage. MAIN OUTCOMES: Patients' temperature, respiration rate, oxygen saturation, lung infiltration, lactate dehydrogenase and complete blood count were measured at the baseline (before the intervention) and on day 14 after the intervention or on the discharge day. RANDOMISATION: The person who has no role in admitting patients and assigning patients to random codes preparing random sequences using online tools and by permuted block randomization method. Eligibility criteria are monitored by the person responsible for admitting patients. Codes in a random sequence are assigned to patients by the treatment team without knowing that each code is in the intervention or comparator group. Patient codes are then matched to randomly generated sequence information for interventions. BLINDING (MASKING): All participants are unaware of which group of this study they are in and after grouping patients in the groups, Patients receive Famotidine in the treatment group and receive a placebo in the control group. The lead researcher, care givers, data collectors, and outcome assessors are aware of the grouping of patients. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): As there is no prior work on this research question, so no assumptions for the sample size calculation could be made. A total of 20 patients participate in this study, which are randomly divided into two groups of 10 as intervention or control groups. TRIAL STATUS: Version 3 of the protocol was approved by the Deputy of Research and Technology and the ethics committee of Hormozgan University of Medical Sciences on August 2, 2020, with the local code 990245, and the recruitment started on August 17, 2020. recruitment ended on August 31, 2020. Since the recruitment ended earlier than expected (the expected recruitment end date was 21/12/2020), we submitted post recruitment but prior to publication of the results. TRIAL REGISTRATION: The protocol was registered before starting subject recruitment under the title: The effect of Famotidine on the improvement of patients with COVID-19, IRCT20200509047364N2, at Iranian Registry of clinical trials ( https://www.irct.ir/trial/49657 ) on 17 August 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Samimagham HR, Hassani Azad M, Haddad M, et al. The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 33050945. doi:10.1186/s13063-020-04773-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。